Products Affected - Description
Cidofovir injection, Heritage Pharmaceuticals
75 mg/mL, 5 mL vial, single count (NDC 23155-0216-31)
Reason for the Shortage
- Gilead discontinued Vistide injection in July 2014.
- Heritage could not provide a reason for the shortage. However, cidofovir injection is manufactured by Emcure for Heritage. An Emcure manufacturing site was recently noted to have FDA observations related to GMP and aseptic practices.
Cidofovir injection, Mylan Institutional
75 mg/mL, 5 mL vial, single count (NDC 67457-0210-05)
Estimated Resupply Dates
Heritage has cidofovir injection temporarily unavailable and the company cannot estimate when product will return.
April 1, March 11, January 14, 2015; November 19, November 10, October 13, September 15, August 29, August 1, July 3, May 12, March 14, January 8, 2014; November 6, September 25, August 22, July 29, June 24, June 6, May 1, April 3, March 29, February 15, 2013, University of Utah, Drug Information Service. Copyright 2015, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins